Drug intelligence / Profile preview

beta-glucan + MM-10-001

Development stage: Phase 1
Modality: Small Molecules
Administration: Oral

Overview

Beta-glucan + MM-10-001 is a combination therapy involving beta-glucans, which are soluble fibers derived from the cell walls of bacteria, fungi, yeasts, and some plants, and the investigational agent MM-10-001. Beta-glucans are known for their immunomodulatory properties and have been studied for their potential roles in cancer prevention and as adjuvants to chemotherapy due to their ability to stimulate immune responses. In clinical studies, oral administration of this combination has been explored in patients with locally advanced or metastatic cancers such as non-small cell lung cancer. The mechanism of action primarily involves immune system activation through modulation of innate immunity[1][2][3][6].

Other names: beta-glucan MM-10-001

Targets

CLEC7A (Dectin-1)

Beyond the preview

Go deeper on beta-glucan + MM-10-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta-glucan + MM-10-001.

Explore the full profile